| Document |
Document Title |
|
WO/2022/025239A1 |
The present disclosure provides a composition for enhancing the therapeutic effect of cell injection therapy, said therapy aiming at treating or preventing a corneal endothelial symptom, disorder or disease. In one embodiment, the presen...
|
|
WO/2022/026336A1 |
The present disclosure provides methods of treating subjects having an immune disorder by administering a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor to the subject, and optionally an E...
|
|
WO/2022/026632A2 |
The present disclosure provides for improved recombinant AAV therapies for the treatment of X-linked retinoschisis (XLRS). These therapies are designed for administration to subjects, such as human subjects, including humans diagnosed wi...
|
|
WO/2022/021636A1 |
Disclosed are a traditional Chinese medicine composition for invigorating the spleen and activating collaterals, and the use thereof. The composition is composed of the following ingredients in parts by weight: 15-25 parts of Puerariae l...
|
|
WO/2022/023463A1 |
The present invention relates to a multi-layer oral pharmaceutical composition comprising a matrix core, comprising a decongestant and a combination of at least two cellulose derivatives, a first layer comprising a cellulose derivative a...
|
|
WO/2022/025430A1 |
The present invention relates to a composition for preventing hearing loss, the composition containing mesenchymal stem cells (MSCs) or exosomes derived therefrom as an active ingredient. Specifically, HSP70 proteins are present in large...
|
|
WO/2022/025204A1 |
The present disclosure provides an anti-EpoR peptide for use in the treatment of a disease such as cancer. In the description, a peptide which has the structure: -[SCHFGPLTWVCK]- and which is intended to be used for antagonizing an Epo h...
|
|
WO/2022/022677A1 |
The present invention relates to a pyrazine compound, a stereoisomer, a tautomer, and a pharmaceutically acceptable salt thereof, which can treat Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal dementia (FT...
|
|
WO/2022/026468A1 |
This invention provides new NGF variants, pharmaceutically acceptable compositions thereof, methods of their production, and methods of their use to treat individuals in need of neuroprotection or stimulation of epithelial-derived cells ...
|
|
WO/2022/019304A1 |
The present invention provides an improvement in the strength of the scleral by collagen fiber crosslinking via crosslinking treatment of the sclera at the equatorial region of the eye and/or at the posterior pole such as the fundus of t...
|
|
WO/2022/019362A1 |
The present invention provides a pharmaceutical composition or a functional health food composition capable of treating or preventing aging-related diseases and disorders by selectively killing senescent cells.
|
|
WO/2022/018605A1 |
The invention discloses a formulation with a combination of genistein and calcitriol (vitamin D) in the management of dry eye disease. The formulation is effective in mitigating the hyperosmotic stress and inflammation in dry eye disease...
|
|
WO/2022/017363A1 |
A pharmaceutical composition for the treatment of Leber congenital amaurosis, and a method for treating Leber congenital amaurosis using the pharmaceutical composition are provided.
|
|
WO/2022/018115A1 |
It is disclosed a Juniperus communis extract comprising at least one compound selected from the group consisting of agathadiol and deoxypodophyllotoxin; and pharmaceutical compositions comprising said extract, for use in the prevention a...
|
|
WO/2022/020424A1 |
Provided herein are compositions and methods for activating pyruvate kinase (e.g., in a subject). In particular, provided herein are compositions and methods for treating a disease or condition (e.g., eye disease, blood disorders, or can...
|
|
WO/2022/019706A1 |
The present invention relates to a trans-splicing ribozyme targeting a rhodopsin transcriptome, and a use thereof for treating and/or preventing retinitis pigmentosa.
|
|
WO/2022/020244A1 |
Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a me...
|
|
WO/2022/018297A1 |
The present invention relates to the use of Alverine or one of its derivatives for treating diseases associated with mitochondrial dysfunction, especially with mitochondrial complex I deficiency.
|
|
WO/2022/020514A1 |
A method of treating and/or preventing age-related retinal dysfunction in a subject in need thereof includes administering to the subject a therapeutically effective amount of an agent that attenuates stress-induced chromatin remodeling ...
|
|
WO/2022/018642A1 |
A composition including a xanthophyll carotenoid diacetate, a transition metal salt, and phospholipids is provided. The composition does not include micelles and is not an emulsion. Methods of supporting eye health in subjects in need th...
|
|
WO/2022/020347A1 |
Biodegradable intraocular implants with a high loading of a prostamide compound for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
|
|
WO/2022/016150A1 |
The present disclosure describes methods for treating cytokine release syndromes, and more particularly to methods using soft corticosteroids to treat the effects of said syndromes in the lungs.
|
|
WO/2022/012304A1 |
An ophthalmic pharmaceutical composition, comprising 0.01-1 wt% of atropine sulfate. The ophthalmic pharmaceutical composition has a pH value of 3.5-4.0 and an osmolality of 180-300 mOsm/kg. The ophthalmic pharmaceutical composition can ...
|
|
WO/2022/014704A1 |
The present invention provides a novel VEGF-binding peptide or a compound including a novel VEGF-binding peptide structure. For example, the present invention provides a compound represented by the following formula (I) (where peptide A ...
|
|
WO/2022/015940A1 |
In certain embodiments, the invention relates to a sustained release biodegradable intracanalicular insert containing a glucocorticoid dispersed in a hydrogel for the treatment of dry eye disease.
|
|
WO/2022/014707A1 |
The present invention relates to the use of a compound having TRPV4 inhibitory activity, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing these, in the manufacture of a pharmaceutical product for the...
|
|
WO/2022/013555A1 |
Anti-angiogenic treatments and compounds for use in anti-angiogenic treatments, particularly of conditions associated with abnormal angiogenesis or abnormal over-production of pro- angiogenic VEGFxxx isoforms in or on the eye are described.
|
|
WO/2022/013787A1 |
The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific ...
|
|
WO/2022/009969A1 |
The present invention provides a method for promoting the engraftment of RPE cells transplanted for treating a retinal degenerative disease such as macular degeneration or retinitis pigmentosa (RP) and a method for preventing rejection o...
|
|
WO/2022/006667A1 |
Method of identifying a subject as having an increased likelihood of progressing to end-organ damage due to diabetes comprising comparing the amount of a lncRNA in a sample from the subject with a reference value, and if the amount of th...
|
|
WO/2022/010271A1 |
Provided is a fusion protein dimer comprising a protein which specifically binds to the extracellular domain of CRIg or a fragment thereof and VEGF. The protein may inhibit complement-related pathways and also may efficiently regulate an...
|
|
WO/2022/007810A1 |
A tricyclic pyrimidinone compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein the compound has a structure as represented by formula (I), is a completely new Lp-PLA2 inhibitor, and can be used for...
|
|
WO/2022/008703A1 |
The invention concerns a dye for use in a method of photoporation of the inner limiting membrane (ILM) of an eye in a subject. Preferably, the method comprises: administering the dye to the vitreous chamber of the eye of the subject; and...
|
|
WO/2022/010273A1 |
Provided is a fusion protein comprising: an extracellular domain of CRIg or a fragment thereof; and CD59 or a mutant thereof. Also, a fusion protein comprising CD59 or a mutant thereof is provided. The proteins can efficiently regulate c...
|
|
WO/2022/008704A1 |
The invention concerns a dye for use in a method of treating a vitreous opacity-related disease in a subject. The method preferably comprises administering the dye to the vitreous body of an affected eye of the subject; and irradiating a...
|
|
WO/2022/007878A1 |
A use of a β-1 adrenoceptor antagonist for preparing a composition for reducing or preventing normal epithelial cell damage induced by an epidermal growth factor receptor inhibitor and inhibiting cancer cells. The composition comprising...
|
|
WO/2022/007869A1 |
The present invention relates to a pyridine or pyrimidine derivative, a preparation method therefor, and a medical use thereof. Specifically, the present invention relates to a pyridine or pyrimidine derivative as shown in general formul...
|
|
WO/2022/010277A1 |
Novel intron fragments are provided. The intron fragments can increase gene expression to levels equal to or higher than those achieved by the full-length intron while maintaining their ability to increase gene expression even when combi...
|
|
WO/2022/008738A1 |
The present disclosure relates to a calcium-activated chloride channel peptide activator and its therapeutic use.
|
|
WO/2022/005012A1 |
The present invention relates to treatment and prevention of allergic diseases and, specifically, to an allergic disease immunomodulation method, which suppresses SIRT7 of nasal cavity epithelial cells to inhibit allergy mediators. The p...
|
|
WO/2022/003063A1 |
The present invention mainly relates to a DNA structure for use in treating an ocular pathology and for the non-viral transfer of nucleic acids into the muscular cells of the eyeball of a patient suffering from the ocular pathology; char...
|
|
WO/2022/002860A1 |
The use of P2X4 antagonists for the treatment of dry eye syndrome, more in particular substituted N-phenylacetamide compounds of general formula (I), pharmaceutical compositions and combinations comprising said compounds for use in the t...
|
|
WO/2022/006439A2 |
Method embodiments are disclosed for treating retinal degeneration in a subject in need thereof. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of compound, and/or a pharmaceutic...
|
|
WO/2022/000492A1 |
The present invention relates to the technical field of biomedicine, relates to a new use of artemisinin or a derivative (artesunate) and dihydroartemisinin artemisinin chloroquine or derivatives (artesunate and dihydroartemisinin) in dr...
|
|
WO/2021/261965A1 |
The present invention relates to a technology for treating retinal neurodegenerative diseases through the regeneration of retinal nerves by targeting Prox1 in the mammalian retina and, more particularly, to: a pharmaceutical composition ...
|
|
WO/2021/260427A1 |
An ophthalmic composition, comprising hyaluronic acid and at least one active ingredient comprising a prostaglandin analogue, wherein the HA acts as a transporting vehicle (transporter) of the prostaglandin analogue into the eye. Said co...
|
|
WO/2021/261712A1 |
The invention relates to hemoglobin derivative, particularly hemoglobin which is co-conjugated with both fatty acid-linked polyethylene glycol (FA-PEG) derivatives and alkoxy polyethylene glycol (alkoxy-PEG) derivatives, and a method for...
|
|
WO/2021/261930A1 |
The present invention pertains to an ophthalmic composition comprising diquafosol, and more specifically, to an ophthalmic composition comprising diquafosol, polysorbate, and dexpanthenol.
|
|
WO/2021/261870A1 |
The present invention relates to a pharmaceutical composition for preventing or treating allergic diseases, or a food composition for ameliorating allergic diseases, comprising 6'-hydroxy Justicidin-B as an active ingredient. 6'-hydroxy ...
|
|
WO/2021/262876A1 |
The present disclosure relates to methods for treating Thyroid Eye Disease (e.g., Graves' Orbitopathy) using Interleukin (IL)-17 antagonists, e.g., secukinumab. Also disclosed herein are IL-17 antagonists, e.g., IL-17 antibodies, such as...
|
